MetLife director acquires 59 shares via dividends

METLIFE INC (MET) director Jeh C. Johnson reported the acquisition of 59 shares of common stock on September 8, 2026 as a grant/award under a non-derivative transaction.

Rhea-AI Filing Summary

METLIFE INC (MET) director Jeh C. Johnson reported the acquisition of 59 shares of common stock on September 8, 2026 as a grant/award under a non-derivative transaction. The shares were credited at an imputed value of $95.50 per share through reinvested dividends on deferred shares.

Following this imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, Johnson now holds 9,557 shares of MetLife common stock in direct ownership, representing deferred shares that have become payable but whose receipt he has elected to defer. No Rule 10b5‑1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 59 shares

Grant/Award 1 txn

Insider Johnson Jeh C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	59	$95.50	$6K

Holdings After Transaction: Common Stock — 9,557 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Shares acquired: 59 shares Imputed value per share: $95.50 per share Total shares following transaction: 9,557 shares +2 more

5 metrics

Shares acquired 59 shares Grant/award acquisition on September 8, 2026 via dividend reinvestment

Imputed value per share $95.50 per share Value used for the 59-share dividend reinvestment credit on September 8, 2026

Total shares following transaction 9,557 shares Director Jeh C. Johnson’s direct holdings after the September 8, 2026 transaction

Number of acquisition transactions 1 transaction Single reported non-derivative grant/award acquisition on this Form 4

Transaction date September 8, 2026 Date of the reported grant/award acquisition of MetLife common stock

Key Terms

Deferred Compensation Plan for Non-Management Directors, imputed reinvestment of dividends, deferred shares

3 terms

Deferred Compensation Plan for Non-Management Directors financial

"pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the"

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

FAQ

What insider transaction did MET (MetLife Inc.) report for Jeh C. Johnson?

MetLife reported that director Jeh C. Johnson acquired 59 shares of common stock on September 8, 2026 as a grant/award tied to reinvested dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

At what value were the new MET shares credited to Jeh C. Johnson?

The 59 MetLife common shares were credited to Jeh C. Johnson at an imputed value of $95.50 per share, reflecting the reinvestment of dividends on deferred shares under the company’s deferred compensation plan for non-management directors.

How many MET shares does Jeh C. Johnson hold after this Form 4 transaction?

After the September 8, 2026 transaction, Jeh C. Johnson is reported as directly holding 9,557 shares of MetLife common stock. These are deferred shares that have become payable, but whose receipt he has chosen to defer under the compensation plan.

Was the September 8, 2026 MET insider transaction under a Rule 10b5-1 plan?

No. The filing indicates the Rule 10b5‑1 plan checkbox is not selected, so the September 8, 2026 acquisition of 59 MetLife shares by Jeh C. Johnson was not reported as being made under a Rule 10b5‑1 trading plan.

What plan governed the MET deferred share transaction for Jeh C. Johnson?

The transaction is described as imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors, under which directors may defer receipt of MetLife common stock that has become payable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:03 PM Accepted by SEC EDGAR 09/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Jeh C.

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		59	A	$95.5	9,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)